Background: Raoultella planticola is a developing pathogen that can infect both humans and animals. Raoultella spp. commonly colonize the gastrointestinal and upper respiratory systems. It usually causes pneumonia, bile tract infections, and bacteremia. Aim: In this study, the anticancer activity of an isolated brown pigment of a Raoultella planticola isolate was tested in vitro. Methods: The laboratory examination included culturing in brain-heart infusion broth, conducting biochemical tests, using the automatic VITEK2 Compact for bacterial isolate identification, performing the MTT assay to evaluate the cytotoxic effect on both the mammary cancer cell line (AMN3) and normal rat fibroblast (REF), and utilizing enzyme-linked immunosorbent assay to measure cytokine levels. Results: R. planticola was found in cow nasal swabs with respiratory problems. The extracted pigment had a significant cytotoxic effect (decreased cell viability) at doses of 2067.5 μg/mL (p < 0.0001 and 0.0001, respectively) and 1033.5 μg/mL (p < 0.0001 and 0.003, respectively). However, the lowest dose (516.875 μg/mL, p > 0.43 and p > 0.18) could not inhibit the growth of malignant or healthy cells. The first and second highest pigment concentrations reduce IL-1β and TNF-α and increase Fas in the AMN3 cell supernatant (p < 0.05). In the AMN3 cell supernatant, the lowest concentration significantly increased IL-1β levels (p < 0.0472) and Fas levels (p < 0.0146), but did not affect TNF-α levels (p < 0.1274). Pigment concentrations at the first and second highest levels significantly reduced IL-1β and TNF-α levels in the REF cell supernatant (p < 0.05), whereas the lowest concentration did not. All pigment doses did not affect the Fas levels in the REF cell supernatant (p > 0.05). Conclusion: In a concentration-dependent manner, the extracted pigment may exert cytotoxic effects and impact cytokine secretion levels in cancerous and normal cell types.
In individuals with type 2 diabetes mellitus (T2DM), the cannabinoid receptor 1 (CNR1) gene polymorphism has been linked to diabetic nephropathy (DN). Different renal disorders, including DN, have been found to alter cannabinoid (CB) receptor expression and activation. This cross-sectional study aimed to investigate the relationship between CNR1 rs1776966256 and rs1243008337 genetic variants and the risk of developing DN in Iraqi patients with T2DM. The study included 100 patients with T2DM, divided into two groups: 50 with DN and 50 without DN. Genotyping of CNR1 rs1776966256 and rs1243008337 polymorphisms was conducted using PCR in DN patients and control samples. The distribution of rs1776966256 and rs1243008337 genotypes and alleles bet
... Show MoreThis assay rapidly detects chlorpromazine hydrochloride using its ability to reduce gold ions to form nanoparticles. Its low cost, resilience to interferences and short analysis time could facilitate environmental monitoring and biomedical analysis.
We describe the synthesis and characterization of a novel 2D-MnOx material using a combination of HR-TEM, XAS, XRD, and reactivity measurements. The ease with which the 2D material can be made and the conditions under which it can be made implies that water oxidation catalysts previously described as “birnessite-like” (3D) may be better thought of as 2D materials with very limited layer stacking. The distinction between the materials as being “birnessite-like” and “2D” is important because it impacts on our understanding of the function of these materials in the environment and as catalysts. The 2D-MnOx material is noted to be a substantially stronger chemical oxidant than previously noted for other birnessite-like manganese oxi
... Show MoreThis assay rapidly detects chlorpromazine hydrochloride using its ability to reduce gold ions to form nanoparticles. Its low cost, resilience to interferences and short analysis time could facilitate environmental monitoring and biomedical analysis.
Checkpoint inhibitors are a type of immune therapy used to treat different types of cancers. These drugs block different checkpoint proteins, for example, CTLA-4, PD-1, and PD-L1 inhibitors.
They block proteins that stop the immune system from attacking the cancer cells. Checkpoints are also described as a type of monoclonal antibody that antagonizes binding between B7 to CTLA-4 and PD-L1 to PD-1.
Immune checkpoint inhibitors are used to treat BARCA mutated triple-negative breast cancer (TNBCS) in patients who do not respond to chemotherapy, and also in the treatment of highly mutated and solid tumors such as brain tumors, liver, and pancreatic cancers.
Immune checkpoint inhibitors exhibit an effect on solid tumo
... Show More